ReviewJournal of infection and public health2023
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
Review in Journal of infection and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 1 synthesis or guideline pooled it, 254 citations in OpenAlex.
- New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.Immunity, inflammation and disease · 2024Pooled it
- Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised Trial.Respirology (Carlton, Vic.) · 2026Trial
- Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg.Drugs in R&D · 2025Trial
- Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.Emerging microbes & infections · 2024Trial
- Randomized trial of influence of vitamin D on the prevention and improvement of symptomatic COVID-19.Scientific reports · 2024Trial
- Gamma SARS-CoV-2 variant of concern infection repercussions on pregnancy outcomes: A translational cohort study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Tracking the shifting landscape of SARS-CoV-2 variants in Lebanon among healthcare workers and hospitalized patients.Microbiology spectrum · 2026Article
- Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.Journal of virology · 2026Article
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein.Molecular biology and evolution · 2026Article
- Article
- Male Sex, Diabetes Mellitus, and an Unvaccinated Status as Deteriorating Factors for Coronavirus Disease 2019 in Patients with Rheumatic Diseases: A Single-center Analysis in the North Kanto Region of Japan During the Omicron Variant Period.Internal medicine (Tokyo, Japan) · 2026Article
- Implementation of SARS-CoV-2 genomic surveillance during the COVID-19 pandemic through an academic-public health collaboration in southeast Michigan.Scientific reports · 2026Article
- Targeting coronaviral inflammation: aptamer-based strategies for emerging threats.Signal transduction and targeted therapy · 2026Article
- Analysis of interception problems in donning and doffing personal protective equipment in a large cabin hospital during the COVID-19 pandemic: a real world study.Scientific reports · 2026Article
- Editorial: Novel natural therapies for infectious diseases using computational and pharmacological approaches.Frontiers in pharmacology · 2026Article
- Predictive and interpretable machine learning for COVID-19 resurgences: the role of SARS-CoV-2 variants in the post-pandemic era.BMC infectious diseases · 2025Article
- Identification of mathematical patterns in genomic spectrograms linked to variant classification in complete SARS-CoV-2 sequences.Scientific reports · 2025Article
- Development and characterization of a bivalent mRNA vaccine targeting the Delta and Omicron variants of SARS-CoV-2.Human vaccines & immunotherapeutics · 2025Article
- Article
- Antigen Format Determines Immunogenicity of AAV-Based SARS-CoV-2 Vaccines: Full-Length Spike Versus Truncated Subunits.Vaccines · 2025Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 16 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves of coronavirus disease 2019 (COVID-19) pandemic. Depending on the extent of genomic variations, mutations and adaptation, few of the variants gain the ability to spread quickly across many countries, acquire higher virulency and ability to cause severe disease, morbidity and mortality. These variants have been implicated in lessening the efficacy of the current COVID-19 vaccines and immunotherapies resulting in break-through viral infections in vaccinated individuals and recovered patients. Altogether, these could hinder the protective herd immunity to be achieved through the ongoing progressive COVID-19 vaccination. Currently, the only variant of interest of SARS-CoV-2 is Omicron that was first identified in South Africa. In this review, we present the overview on the emerging SARS-CoV-2 variants with a special focus on the Omicron variant, its lineages and hybrid variants. We discuss the hypotheses of the origin, genetic change and underlying molecular mechanism behind higher transmissibility and immune escape of Omicron variant. Major concerns related to Omicron including the efficacy of the current available immunotherapeutics and vaccines, transmissibility, disease severity, and mortality are discussed. In the last part, challenges and strategies to counter Omicron variant, its lineages and hybrid variants amid the ongoing COVID-19 pandemic are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.